Tumour-associated macrophages: versatile players in the tumour microenvironment.
immunotherapy
macrophage plasticity
macrophage-myofibroblast transition
macrophage-neuron transition
tumour microenvironment
tumour-associated macrophages
Journal
Frontiers in cell and developmental biology
ISSN: 2296-634X
Titre abrégé: Front Cell Dev Biol
Pays: Switzerland
ID NLM: 101630250
Informations de publication
Date de publication:
2023
2023
Historique:
received:
19
07
2023
accepted:
12
10
2023
medline:
15
11
2023
pubmed:
15
11
2023
entrez:
15
11
2023
Statut:
epublish
Résumé
Tumour-Associated Macrophages (TAMs) are one of the pivotal components of the tumour microenvironment. Their roles in the cancer immunity are complicated, both pro-tumour and anti-cancer activities are reported, including not only angiogenesis, extracellular matrix remodeling, immunosuppression, drug resistance but also phagocytosis and tumour regression. Interestingly, TAMs are highly dynamic and versatile in solid tumours. They show anti-cancer or pro-tumour activities, and interplay between the tumour microenvironment and cancer stem cells and under specific conditions. In addition to the classic M1/M2 phenotypes, a number of novel dedifferentiation phenomena of TAMs are discovered due to the advanced single-cell technology, e.g., macrophage-myofibroblast transition (MMT) and macrophage-neuron transition (MNT). More importantly, emerging information demonstrated the potential of TAMs on cancer immunotherapy, suggesting by the therapeutic efficiency of the checkpoint inhibitors and chimeric antigen receptor engineered cells based on macrophages. Here, we summarized the latest discoveries of TAMs from basic and translational research and discussed their clinical relevance and therapeutic potential for solid cancers.
Identifiants
pubmed: 37965573
doi: 10.3389/fcell.2023.1261749
pii: 1261749
pmc: PMC10641386
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1261749Informations de copyright
Copyright © 2023 Ji, Chan, Chan, Leung, Jiang, To, Wu and Tang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Immunother Cancer. 2023 Mar;11(3):
pubmed: 36914207
Biomaterials. 2021 Jan;267:120412
pubmed: 33161320
Cell Biochem Funct. 2023 Jul;41(5):542-552
pubmed: 37170668
JCI Insight. 2020 Feb 27;5(4):
pubmed: 32102987
Cell Death Discov. 2022 Dec 5;8(1):480
pubmed: 36470862
Clin Cancer Res. 2019 Jun 1;25(11):3289-3303
pubmed: 30755440
Cancer Biol Ther. 2019;20(7):956-966
pubmed: 31062668
J Clin Invest. 2018 Dec 3;128(12):5647-5662
pubmed: 30352428
Cell Rep. 2021 Oct 19;37(3):109844
pubmed: 34686340
Front Immunol. 2018 Nov 13;9:2629
pubmed: 30483271
Clin Cancer Res. 2021 Nov 1;27(21):6054-6064
pubmed: 34376537
Mol Cancer. 2023 Feb 16;22(1):34
pubmed: 36797782
Mol Cancer. 2022 Sep 8;21(1):177
pubmed: 36071472
Br J Cancer. 2023 Jun;128(11):2104-2115
pubmed: 37002343
Biomaterials. 2021 Nov;278:121137
pubmed: 34560422
Signal Transduct Target Ther. 2023 Mar 7;8(1):104
pubmed: 36882399
J Immunol. 2018 Feb 1;200(3):1008-1015
pubmed: 29282306
Am J Physiol Lung Cell Mol Physiol. 2019 Nov 1;317(5):L539-L549
pubmed: 31411060
Signal Transduct Target Ther. 2020 Aug 25;5(1):166
pubmed: 32843638
Front Cardiovasc Med. 2023 May 05;10:1136252
pubmed: 37215542
Front Immunol. 2019 Nov 15;10:2689
pubmed: 31803194
Int J Oncol. 2023 Jan;62(1):
pubmed: 36331032
Mol Metab. 2018 Jan;7:23-34
pubmed: 29153923
Cell Commun Signal. 2022 Jan 3;20(1):2
pubmed: 34980167
Nature. 2022 Dec;612(7940):555-563
pubmed: 36450983
Front Immunol. 2021 Jun 03;12:618501
pubmed: 34149684
Nature. 2021 Mar;591(7851):652-658
pubmed: 33588426
Technol Cancer Res Treat. 2019 Jan 1;18:1533033819874807
pubmed: 31522611
Br J Cancer. 2019 Jul;121(1):22-33
pubmed: 31130723
Mol Biol Rep. 2022 May;49(5):3469-3480
pubmed: 35107742
J Clin Invest. 2020 Oct 1;130(10):5380-5396
pubmed: 32663198
Front Physiol. 2019 Jul 25;10:914
pubmed: 31404148
Cancers (Basel). 2022 Jun 01;14(11):
pubmed: 35681730
Commun Med (Lond). 2023 Feb 7;3(1):14
pubmed: 36750617
Cell Rep Med. 2023 Mar 21;4(3):100939
pubmed: 36796366
Nat Commun. 2022 Jun 2;13(1):3072
pubmed: 35654768
Front Immunol. 2023 Mar 07;14:997376
pubmed: 36960049
Nat Immunol. 2022 Aug;23(8):1148-1156
pubmed: 35879449
Front Immunol. 2022 May 03;13:874589
pubmed: 35592338
Sci Rep. 2021 Sep 8;11(1):17842
pubmed: 34497300
J Inflamm (Lond). 2021 Jan 7;18(1):2
pubmed: 33413430
Immunity. 2022 Nov 8;55(11):2085-2102.e9
pubmed: 36228615
Noncoding RNA. 2022 May 25;8(3):
pubmed: 35736633
Signal Transduct Target Ther. 2021 Feb 15;6(1):62
pubmed: 33589595
Sci Rep. 2019 Oct 10;9(1):14611
pubmed: 31601953
Nature. 2023 Mar;615(7953):697-704
pubmed: 36890230
Int J Biochem Cell Biol. 2022 Dec;153:106330
pubmed: 36343916
J Hematol Oncol. 2022 Jan 6;15(1):2
pubmed: 34991659
Neoplasia. 2020 Nov;22(11):606-616
pubmed: 33039895
Nature. 2022 Sep;609(7926):348-353
pubmed: 35978195
Front Immunol. 2022 Apr 04;13:860262
pubmed: 35444643
Oncoimmunology. 2017 Nov 6;7(2):e1391973
pubmed: 29308321
J Control Release. 2023 Apr 12;:
pubmed: 37080897
Science. 2020 Jul 17;369(6501):
pubmed: 32675345
Nat Rev Drug Discov. 2019 Feb;18(2):99-115
pubmed: 30470818
Med Oncol. 2022 May 16;39(5):83
pubmed: 35570226
Nat Cell Biol. 2022 Jun;24(6):954-967
pubmed: 35637408
J Transl Med. 2023 Jan 14;21(1):26
pubmed: 36641471
Cell. 2021 Feb 4;184(3):792-809.e23
pubmed: 33545035
Clin Cancer Res. 2015 May 15;21(10):2325-37
pubmed: 25717063
Int J Biol Sci. 2021 Jul 25;17(13):3281-3287
pubmed: 34512146
Cell Stem Cell. 2023 May 4;30(5):592-610
pubmed: 36948187
Cell Biol Int. 2021 Apr;45(4):831-838
pubmed: 33325089
Arthritis Res Ther. 2022 Nov 04;24(1):249
pubmed: 36333776
JCI Insight. 2018 Nov 2;3(21):
pubmed: 30385721
Proc Natl Acad Sci U S A. 2020 Aug 25;117(34):20741-20752
pubmed: 32788346
Pharmacol Res. 2022 Sep;183:106376
pubmed: 35914680
Cell Mol Immunol. 2023 Jan;20(1):65-79
pubmed: 36471114
Cancer Immunol Res. 2020 Feb;8(2):246-254
pubmed: 31852717
Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17686-91
pubmed: 20861446
Proc Natl Acad Sci U S A. 2023 Jan 17;120(3):e2209184120
pubmed: 36626553
Front Immunol. 2018 Oct 05;9:2314
pubmed: 30344524
Clin Transl Med. 2021 Sep;11(9):e478
pubmed: 34586722
Proc Natl Acad Sci U S A. 2020 Jan 14;117(2):1129-1138
pubmed: 31879345
J Hematol Oncol. 2020 Oct 15;13(1):136
pubmed: 33059744
Theranostics. 2019 May 9;9(10):2950-2966
pubmed: 31244935
Cancer Immunol Res. 2022 Nov 2;10(11):1354-1369
pubmed: 36095236
Science. 2013 Jan 18;339(6117):286-91
pubmed: 23329041
Nat Rev Drug Discov. 2018 Dec;17(12):887-904
pubmed: 30361552
Cell. 2022 Mar 31;185(7):1189-1207.e25
pubmed: 35325594
J Allergy Clin Immunol. 2022 Jun;149(6):2078-2090
pubmed: 34974067
JCI Insight. 2021 Jun 22;6(12):
pubmed: 34032639
Proc Natl Acad Sci U S A. 2018 Aug 21;115(34):E8057-E8066
pubmed: 30082378
Cancers (Basel). 2021 Jun 19;13(12):
pubmed: 34205330
Mol Cancer. 2023 Feb 21;22(1):38
pubmed: 36810098
Proc Natl Acad Sci U S A. 2020 Dec 1;117(48):30628-30638
pubmed: 33199625
Clin Transl Med. 2022 May;12(5):e847
pubmed: 35538869
Nat Cancer. 2023 Apr;4(4):468-484
pubmed: 36914817
Front Immunol. 2021 Feb 23;12:619195
pubmed: 33708210
EMBO Rep. 2022 Jul 5;23(7):e54339
pubmed: 35574994
Cancer Immunol Immunother. 2021 Aug;70(8):2401-2410
pubmed: 33511454
Cell Prolif. 2021 Oct;54(10):e13115
pubmed: 34464477
Cell Death Dis. 2023 Mar 29;14(3):222
pubmed: 36990999
Nat Commun. 2020 Aug 13;11(1):4064
pubmed: 32792542
Cancer Res. 2019 Feb 15;79(4):795-806
pubmed: 30610087
Adv Sci (Weinh). 2019 Aug 27;6(20):1900513
pubmed: 31637157
Cell Death Dis. 2018 Sep 5;9(9):905
pubmed: 30185773
J Exp Med. 2019 May 6;216(5):1170-1181
pubmed: 30910796
Genes Immun. 2022 Jun;23(3-4):129-140
pubmed: 35525858
Cell Mol Immunol. 2021 Mar;18(3):579-587
pubmed: 32934339
Mol Cancer. 2023 Jan 30;22(1):20
pubmed: 36717905
Cancer Discov. 2020 Nov;10(11):1758-1773
pubmed: 32651166
Cold Spring Harb Perspect Biol. 2014 Jun 02;6(6):
pubmed: 24890514
Cell Death Dis. 2018 Sep 11;9(9):928
pubmed: 30206229
NPJ Precis Oncol. 2021 Jun 22;5(1):56
pubmed: 34158591
Elife. 2023 Mar 06;12:
pubmed: 36876914
J Cell Mol Med. 2021 Oct;25(20):9805-9813
pubmed: 34514726
Neurosurgery. 2023 Mar 1;92(3):581-589
pubmed: 36729787
J Immunother Cancer. 2021 Apr;9(4):
pubmed: 33879600
Nat Rev Mol Cell Biol. 2019 Feb;20(2):69-84
pubmed: 30459476
Clin Cancer Res. 2022 Apr 14;28(8):1734
pubmed: 35419588
Nat Commun. 2021 Jul 27;12(1):4558
pubmed: 34315904
Nat Immunol. 2021 Feb;22(2):118-127
pubmed: 33462453
Nat Commun. 2018 Apr 27;9(1):1685
pubmed: 29703902
Genome Biol. 2020 Aug 26;21(1):216
pubmed: 32847614
J Clin Invest. 2022 Mar 1;132(5):
pubmed: 35085106
Eur J Epidemiol. 2021 Aug;36(8):841-848
pubmed: 34036468
Clin Cancer Res. 2020 Feb 15;26(4):970-977
pubmed: 31615933
Cancers (Basel). 2020 Oct 21;12(10):
pubmed: 33096662
Mol Ther Oncolytics. 2022 Jun 22;26:158-174
pubmed: 35860009
Lung Cancer. 2019 Oct;136:136-144
pubmed: 31499335
Cancer Immunol Res. 2021 Jan;9(1):8-19
pubmed: 33023967
Mol Ther. 2021 Jan 6;29(1):365-375
pubmed: 32956626
Nat Commun. 2020 Jul 30;11(1):3816
pubmed: 32732870
J Transl Med. 2021 Jul 5;19(1):290
pubmed: 34225749
Oncogene. 2021 Jan;40(2):396-407
pubmed: 33159168
Front Immunol. 2023 Mar 07;14:919800
pubmed: 36960051
Cancer Cell Int. 2021 Jul 21;21(1):389
pubmed: 34289846
Nat Biotechnol. 2020 Aug;38(8):947-953
pubmed: 32361713
Nat Commun. 2019 Nov 1;10(1):5016
pubmed: 31676788
Cancer Cell Int. 2022 Mar 17;22(1):122
pubmed: 35300689
Cancer Cell Int. 2021 Dec 18;21(1):677
pubmed: 34922542
Methods Mol Biol. 2023;2572:1-37
pubmed: 36161404
Cancer Res Treat. 2019 Jan;51(1):252-266
pubmed: 29690747
Gastroenterology. 2021 Aug;161(2):592-607
pubmed: 33930428
Nat Commun. 2020 Jul 20;11(1):3631
pubmed: 32686670
Int Rev Cell Mol Biol. 2019;342:73-93
pubmed: 30635094
J Control Release. 2021 Aug 10;336:344-353
pubmed: 34147573
J Leukoc Biol. 2020 Mar;107(3):445-453
pubmed: 32017192
Cell Rep. 2023 Apr 25;42(4):112346
pubmed: 37022934
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33115946
Cancer Immunol Res. 2022 May 3;10(5):612-625
pubmed: 35303066
Sci Adv. 2022 Oct 7;8(40):eabn5535
pubmed: 36206343
J Cancer. 2021 Jan 1;12(4):976-987
pubmed: 33442397
J Control Release. 2022 May;345:306-313
pubmed: 35301053
Cell Rep. 2018 Mar 6;22(10):2642-2653
pubmed: 29514093
Cell Oncol (Dordr). 2019 Feb;42(1):81-92
pubmed: 30276551
J Clin Invest. 2019 Mar 1;129(3):1278-1294
pubmed: 30628894
Front Immunol. 2021 Oct 22;12:760322
pubmed: 34745135
Cancer Immunol Immunother. 2019 Dec;68(12):2081-2094
pubmed: 31720815
Biomed Pharmacother. 2018 Jul;103:262-271
pubmed: 29656182
Sci Rep. 2019 Nov 14;9(1):16752
pubmed: 31727941
J Exp Med. 2019 Oct 7;216(10):2394-2411
pubmed: 31375534
J Exp Med. 2020 Jan 6;217(1):
pubmed: 31611251
Nat Commun. 2022 Oct 10;13(1):5974
pubmed: 36216803
Adv Sci (Weinh). 2019 Apr 10;6(11):1900195
pubmed: 31179226
Elife. 2022 Aug 19;11:
pubmed: 35983991
Trends Endocrinol Metab. 2023 Nov;34(11):749-763
pubmed: 37633799
Cell Rep. 2021 Mar 30;34(13):108917
pubmed: 33789113
Cell Mol Immunol. 2022 Apr;19(4):540-553
pubmed: 35194174
Cancer Cell. 2022 Oct 10;40(10):1207-1222.e10
pubmed: 36084651
J Transl Med. 2020 Nov 23;18(1):443
pubmed: 33228719
Sci Rep. 2019 Feb 4;9(1):1223
pubmed: 30718924
Cancer Cell. 2023 Apr 10;41(4):693-710.e8
pubmed: 36963400
Cell Rep. 2022 Mar 29;38(13):110565
pubmed: 35354043
Cell. 2020 Aug 20;182(4):872-885.e19
pubmed: 32783915
Cell Mol Life Sci. 2020 May;77(9):1745-1770
pubmed: 31690961
Oncogene. 2022 Feb;41(6):865-877
pubmed: 34862460
JCI Insight. 2021 Mar 22;6(6):
pubmed: 33591958
Nat Commun. 2020 Oct 9;11(1):5120
pubmed: 33037194
Mol Cancer Ther. 2017 Feb;16(2):312-322
pubmed: 27980102
Mol Cancer. 2022 Sep 1;21(1):173
pubmed: 36045408
Commun Biol. 2020 Nov 27;3(1):720
pubmed: 33247183
Front Oncol. 2022 Jan 12;11:793881
pubmed: 35096592
Sci Rep. 2019 May 13;9(1):7295
pubmed: 31086251
J Inflamm Res. 2021 Dec 23;14:7315-7329
pubmed: 34992419
EBioMedicine. 2022 Feb;76:103873
pubmed: 35152151
Cancer Cell. 2019 Apr 15;35(4):588-602.e10
pubmed: 30930117
Cell Mol Immunol. 2021 Jan;18(1):45-56
pubmed: 33041338
Mol Ther Oncolytics. 2021 Aug 25;23:26-37
pubmed: 34589582
J Hematol Oncol. 2020 Nov 19;13(1):156
pubmed: 33213490
Hepatology. 2019 Oct;70(4):1262-1279
pubmed: 30991448
Int J Mol Sci. 2022 Dec 08;23(24):
pubmed: 36555168
Cancers (Basel). 2021 Oct 22;13(21):
pubmed: 34771482
Front Immunol. 2017 Apr 21;8:404
pubmed: 28484448
Cancer Cell Int. 2018 Aug 28;18:120
pubmed: 30181713
Biochim Biophys Acta Mol Cell Res. 2021 May;1868(6):118995
pubmed: 33667527
J Hepatol. 2021 Nov;75(5):1192-1202
pubmed: 34242696
Cell Rep Med. 2021 Nov 16;2(11):100449
pubmed: 34841295
Mucosal Immunol. 2022 Feb;15(2):223-234
pubmed: 35017701
Sci Rep. 2019 Oct 1;9(1):14050
pubmed: 31575880
Cancer Immunol Immunother. 2022 Nov;71(11):2645-2661
pubmed: 35352168
J Cell Immunol. 2020;2(3):108-115
pubmed: 32719831
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
J Immunother Cancer. 2023 Jan;11(1):
pubmed: 36593065
Cell Death Dis. 2019 Dec 4;10(12):918
pubmed: 31801938
Biomed Pharmacother. 2019 Sep;117:109096
pubmed: 31202170
Genome Med. 2020 Jun 24;12(1):55
pubmed: 32580776
Front Immunol. 2018 Apr 09;9:688
pubmed: 29686677
Cell Mol Immunol. 2022 Sep;19(9):1054-1066
pubmed: 35962191
J Am Chem Soc. 2022 Jun 8;144(22):9723-9733
pubmed: 35617327
Signal Transduct Target Ther. 2023 May 11;8(1):198
pubmed: 37169756
EBioMedicine. 2019 Oct;48:70-80
pubmed: 31629677
Cancer Res. 2021 Feb 15;81(4):956-967
pubmed: 33293426
Cancer Lett. 2020 Sep 1;487:74-84
pubmed: 32470491
Proc Natl Acad Sci U S A. 2019 Jan 22;116(4):1361-1369
pubmed: 30545915
Nat Immunol. 2022 Sep;23(9):1365-1378
pubmed: 35999394
Nat Rev Nephrol. 2019 Mar;15(3):144-158
pubmed: 30692665
Nature. 2019 Oct;574(7779):565-570
pubmed: 31645726
Mol Ther. 2018 Jan 3;26(1):148-161
pubmed: 29102563
Nat Commun. 2019 Sep 3;10(1):3974
pubmed: 31481662
Front Immunol. 2019 Apr 09;10:705
pubmed: 31024544
Clin Cancer Res. 2021 Aug 1;27(15):4205-4220
pubmed: 34078651
Signal Transduct Target Ther. 2021 Aug 4;6(1):291
pubmed: 34344870
J Immunol. 2015 Sep 15;195(6):2818-28
pubmed: 26276870
J Cell Biol. 2023 May 1;222(5):
pubmed: 36988579
Adv Sci (Weinh). 2022 Jan;9(1):e2101235
pubmed: 34791825
Nature. 2020 Apr;580(7802):257-262
pubmed: 32269339
World J Surg Oncol. 2018 Jan 16;16(1):9
pubmed: 29338742
Nat Commun. 2022 Mar 16;13(1):1371
pubmed: 35296660
J Cell Physiol. 2020 Nov;235(11):8679-8690
pubmed: 32324268
Nat Cancer. 2021 Nov;2(11):1185-1203
pubmed: 35122059
Proc Natl Acad Sci U S A. 2002 Feb 5;99(3):1503-8
pubmed: 11805289
Front Immunol. 2022 Feb 25;13:814967
pubmed: 35281038
Gastroenterology. 2019 Mar;156(4):1156-1172.e6
pubmed: 30445007
Signal Transduct Target Ther. 2021 Mar 8;6(1):109
pubmed: 33678805
Prostate. 2019 Mar;79(4):363-369
pubmed: 30500076
J Cell Mol Med. 2019 Feb;23(2):1257-1267
pubmed: 30456891
J Immunol Res. 2020 Oct 13;2020:9731049
pubmed: 33110923
J Biomed Sci. 2022 Dec 22;29(1):109
pubmed: 36550569
Cardiovasc Res. 2020 Oct 1;116(12):2021-2030
pubmed: 31710666
Nat Cardiovasc Res. 2022 Jan;1(1):67-84
pubmed: 35599984
J Immunol. 2012 Sep 15;189(6):3168-77
pubmed: 22869907
J Exp Med. 2021 Jul 5;218(7):
pubmed: 33974041
Oncogene. 2021 Mar;40(10):1836-1850
pubmed: 33564072
Commun Biol. 2022 May 31;5(1):519
pubmed: 35641589
Nat Commun. 2023 Mar 31;14(1):1794
pubmed: 37002229
J Immunother Cancer. 2022 Mar;10(3):
pubmed: 35338085
Trends Immunol. 2004 Apr;25(4):201-9
pubmed: 15039047
J Oral Pathol Med. 2019 Sep;48(8):677-685
pubmed: 31134686
Nat Commun. 2021 Feb 9;12(1):877
pubmed: 33563975
Genome Med. 2021 Apr 20;13(1):64
pubmed: 33879239
Adv Pharmacol. 2018;81:241-330
pubmed: 29310800
BMC Cancer. 2020 Apr 5;20(1):277
pubmed: 32248797
Cell. 2020 Aug 20;182(4):886-900.e17
pubmed: 32783918
Cell Death Dis. 2021 Aug 30;12(9):818
pubmed: 34462422
Sci Transl Med. 2021 Jun 16;13(598):
pubmed: 34135110
Clin Cancer Res. 2020 Sep 15;26(18):4970-4982
pubmed: 32586940
Cell Rep. 2020 Mar 31;30(13):4386-4398.e5
pubmed: 32234475
Cell Mol Immunol. 2023 Jan;20(1):38-50
pubmed: 36376488
Proc Natl Acad Sci U S A. 2012 Apr 24;109(17):6662-7
pubmed: 22451913
Sci Transl Med. 2020 Feb 12;12(530):
pubmed: 32051227
J Immunother Cancer. 2020 Oct;8(2):
pubmed: 33020240
Nat Rev Drug Discov. 2022 Nov;21(11):799-820
pubmed: 35974096
Protein Cell. 2018 Dec;9(12):1027-1038
pubmed: 29508278
J Neurosci. 2020 Dec 9;40(50):9602-9616
pubmed: 33158964
J Clin Invest. 2022 Feb 1;132(3):
pubmed: 34874921
Clin Exp Immunol. 2023 Mar 16;211(2):176-183
pubmed: 36571811
J Clin Invest. 2023 Aug 1;133(15):
pubmed: 37526085
Front Oncol. 2023 Mar 08;13:1052201
pubmed: 36969026
Biomaterials. 2019 Mar;196:90-99
pubmed: 30075952
Cell Rep. 2021 Nov 2;37(5):109955
pubmed: 34731634
Cancer Immunol Res. 2022 Jan;10(1):40-55
pubmed: 34795032
J Clin Invest. 2019 Dec 2;129(12):5518-5536
pubmed: 31710308
Cell Biosci. 2022 Jun 7;12(1):85
pubmed: 35672862
Environ Sci Technol. 2022 Dec 6;56(23):17029-17038
pubmed: 36394988
Front Cell Infect Microbiol. 2020 Jun 12;10:287
pubmed: 32596169
Nat Commun. 2019 Jun 28;10(1):2863
pubmed: 31253779
Blood. 2021 Feb 4;137(5):678-689
pubmed: 33538796
Cells. 2020 May 15;9(5):
pubmed: 32429133
Cell Rep. 2022 Dec 13;41(11):111828
pubmed: 36516765
Nat Commun. 2017 Mar 06;8:14677
pubmed: 28262747
Cancer Cell Int. 2020 Jun 24;20:266
pubmed: 32595415
Front Immunol. 2018 Jul 19;9:1650
pubmed: 30072995
Signal Transduct Target Ther. 2020 Feb 7;5(1):8
pubmed: 32296030
Nat Biomed Eng. 2023 Sep;7(9):1081-1096
pubmed: 37095318
Cancer Immunol Res. 2020 Aug;8(8):1004-1017
pubmed: 32532809
Elife. 2022 Sep 29;11:
pubmed: 36173104
Cell Death Dis. 2018 Jan 25;9(2):115
pubmed: 29371595
Nature. 2023 Feb;614(7946):136-143
pubmed: 36470303